Effect of peramivir on respiratory symptom improvement in patients with respiratory disease -comparatve evaluation: peramivir maximal dose (600mg) repeat-dosing (2days) vs standard dose (300mg) single-dosing vs oseltamivir (75mg bid) 5days treatment-

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 05 Jul 2020

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Peramivir (Primary) ; Oseltamivir
Indications Influenza A virus infections; Influenza B virus infections
Focus Therapeutic Use
Sponsors Shionogi

Most Recent Events

20 May 2020 Results presented at the 116th International Conference of the American Thoracic Society
30 Jan 2019 Status changed from recruiting to completed.
28 May 2018 Status changed from not yet recruiting to recruiting.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight